Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Retained Earnings: 2023-2025

Historic Retained Earnings for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$658.3 million.

  • Immunome's Retained Earnings fell 51.15% to -$658.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$658.3 million, marking a year-over-year decrease of 51.15%. This contributed to the annual value of -$515.8 million for FY2024, which is 131.49% down from last year.
  • Immunome's Retained Earnings amounted to -$658.3 million in Q3 2025, which was down 9.57% from -$600.8 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Retained Earnings ranged from a high of -$120.3 million in Q1 2023 and a low of -$658.3 million during Q3 2025.
  • Moreover, its 3-year median value for Retained Earnings was -$388.4 million (2024), whereas its average is -$373.4 million.
  • Data for Immunome's Retained Earnings shows a maximum YoY crashed of 234.50% (in 2024) over the last 5 years.
  • Over the past 3 years, Immunome's Retained Earnings (Quarterly) stood at -$222.8 million in 2023, then crashed by 131.49% to -$515.8 million in 2024, then tumbled by 51.15% to -$658.3 million in 2025.
  • Its Retained Earnings stands at -$658.3 million for Q3 2025, versus -$600.8 million for Q2 2025 and -$557.4 million for Q1 2025.